Orforglipron (12 mg and 36 mg) achieved statistically superior HbA1c reductions compared to both 7 mg and 14 mg doses of oral semaglutide over 52 weeks.
As a non-peptide GLP-1 receptor agonist, orforglipron simplifies treatment by removing food and water restrictions associated with current oral peptide therapies.
The superior efficacy was accompanied by a higher incidence of gastrointestinal adverse events and a higher rate of treatment discontinuation compared to oral semaglutide.
Mean pulse rate increases were more pronounced in the orforglipron treatment arms.
Background: The Evolution of Oral Incretin Therapies
